Home > Haematological Malignancies
    • FILTER YOUR SEARCH
    Content Type:

    • Haematological Malignancies

    INTERNATIONAL HAEMATOLOGICAL MALIGNANCIES PARTNER

    An Introduction to Haematological Malignancies

    In recent years, advances in our understanding of the pathological mechanisms underlying haematological malignancies have led to improved outcomes. Several novel drug classes are now emerging, including chimeric antigen receptor (CAR) T-cell therapy, molecular targeted therapies, bispecific T-cell engaging antibodies, CD47 blockade therapy and antibody-drug conjugates. Many challenges remain, however, including how best to combine agents and determining where new therapies fit into the treatment paradigm.

    Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.”

    Our supporting partners do not constitute an endorsement of the content on this page.

    Haematological Malignancies Content

    Multiple Myeloma
    touchPANEL DISCUSSION
    Improving outcomes in multiple myeloma with new treatment targets?
    CME ACCREDITED Prof. Joseph Mikhael, Dr Cristina Gasparetto, Dr Elena Zamagni Watch Time: 33 mins

    Watch a panel of experts discuss how novel targeted therapies are changing the treatment paradigm for multiple myeloma to achieve the best outcomes for patients.

    Learning objectives
    Learning Objectives
    • Recall the mechanisms of action and data for relapsed/refractory multiple myeloma treatments with novel agents
    • Discuss the adverse event (AE) profiles of treatments with novel targets and how AEs could be managed in clinical practice
    • Describe the possible role of agents with novel targets earlier in the multiple myeloma treatment pathway
    Haematological Malignancies, Haematology, Lymphoma
    touchEXPERT OPINIONS
    New and emerging strategies for managing patients with relapsed/refractory follicular lymphoma: latest advances in prognostics and treatment
    CME ACCREDITED Prof. Kami Maddocks, Dr Connie Lee Batlevi, Dr Laurie Sehn Watch Time: 40 mins

    Watch leading lymphoma specialists provide updates on prognostic factors and novel treatment strategies for patients with relapsed/refractory follicular lymphoma

    Learning objectives
    Learning Objectives
    • Evaluate the key prognostic factors that indicate high risk of inferior outcomes in patients with FL
    • Evaluate novel and emerging treatment strategies for patients with R/R FL
    • Translate the latest clinical data for EZH2 and PI3K inhibitors in patients with R/R FL into clinical practice
    Haematological Malignancies, Immunotherapy, Leukaemia, Lymphoma
    touchPANEL DISCUSSION
    What is the current state of play of CAR T-cell therapy for B-cell malignancies? Focus on patient selection, safety and new indications
    Prof. Christian Chabannon, Prof. Chiara Bonini, Prof. Dr. Peter Borchmann Watch Time: 45 mins Available in:

    Learn about patient selection for chimeric antigen receptor (CAR) T-cell therapy, adverse event management and the latest developments in CAR T-cell therapies for B-cell malignancies from experts in the field.

    Learning objectives
    Learning Objectives
    • Describe patients who may be eligible for treatment with CAR T-cell therapy
    • Review the management of adverse events associated with CAR T-cell therapy
    • Discuss how CAR T-cell therapy might impact the treatment pathway for new indications
    Haematological Malignancies, Immunotherapy, Leukaemia, Lymphoma
    touchEXPERT OPINIONS
    Optimizing care with CAR T-cell therapy now and in the future for patients with B-cell malignancies
    Prof. Catherine Thieblemont, Prof. Dr. Marion Subklewe, Dr Maeve O’Reilly, Prof. Adriana Balduzzi, Dr Michael Dickinson Watch Time: 58 mins Available in:

    Get an update on chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies, including guidance on referral and toxicity management, in these interviews with five experts.

    Learning objectives
    Learning Objectives
    • Recall the latest clinical trial and real-world data for CAR T-cell therapies in the management of B-cell malignancies
    • Describe which patients are eligible for CAR T-cell therapy and discuss the optimal time for referral
    • Discuss the safety profile of CAR T-cell therapy and the associated management strategies
    • Describe data for new and emerging indications for CAR T-cell therapy
    Leukaemia
    Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML

    touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic […]

    Leukaemia
    Othman Al-Sawaf, ASH 2020 – Venetoclax-obinutuzumab and the CLL14 Trial

    Dr Othman Al-Sawaf joins touchONCOLOGY to discuss the CLL14 trial and the impact of venetoclax-obinutuzumab treatment on clonal growth and the potential of its use in chronic lymphocytic leukaemia. The abstract ‘Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial’ (Abstract number 127) was presented at the 62nd American Society […]

    Multiple Myeloma
    Shaji Kumar, ASH 2020 – Highlights from ASH 2020

    It was a pleasure to speak with our Editor-in-Chief, Shaji Kumar (Mayo Clinic, Rochester, MN, USA) to discuss the use of MEDI2228 (Clinical Trial Identifier: NCT03489525) and anti-BCMA CAR-T cells (Clinical Trial Identifier: NCT03915184) in the treatment of patients with relapsed/refractory multiple myeloma and to find out his personal highlights from this year’s congress. The […]

    Multiple Myeloma
    Latest Developments in Cellular Therapy for Multiple Myeloma
    Tara K Gregory, Henning Schade, Jesús G Berdeja

    Oncology & Hematology Review (US). 2020;16(2):111-8 DOI: https://doi.org/10.17925/OHR.2021.16.2.111

    Multiple myeloma (MM) is a malignant clonal disorder of plasma cells in the bone marrow, and more than 32,000 new cases are expected in the USA each year.1 Many clinical advances, including novel drugs and continuous therapy with treatment sequencing, have improved survival statistics.2 Despite this, MM remains largely incurable and the relapsed/refractory population remains vulnerable […]

    Multiple Myeloma
    Meletios-Athanasios Dimopoulos, ASH 2020 – Results from the Apollo Trial

    We caught up with Meletios-Athanasios Dimopoulos (National and Kapodistrian University of Athens School of Medicine, Athens, Greece) to discuss his ASH 2020 presentation on the use of daratumumab in the treatment of relapsed/refractory multiple myeloma (Clinical Trial Identification: NCT03180736). The abstract ‘412 Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) […]

    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72